Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,146,664
  • Shares Outstanding, K 196,323
  • Annual Sales, $ 4,241 M
  • Annual Income, $ 32,610 K
  • EBIT $ 1,481 M
  • EBITDA $ 1,570 M
  • 60-Month Beta 0.82
  • Price/Sales 4.29
  • Price/Cash Flow 191.85
  • Price/Book 4.48

Options Overview Details

View History
  • Implied Volatility 40.17% (+0.51%)
  • Historical Volatility 38.95%
  • IV Percentile 60%
  • IV Rank 38.31%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 30) 9.35 (8.89%)
  • Put/Call Vol Ratio 0.25
  • Today's Volume 376
  • Volume Avg (30-Day) 848
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 13,686
  • Open Int (30-Day) 18,002
  • Expected Range 95.78 to 114.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.66
  • Number of Estimates 8
  • High Estimate 1.81
  • Low Estimate 1.53
  • Prior Year 1.09
  • Growth Rate Est. (year over year) +52.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.63 +7.79%
on 12/29/25
112.29 -6.28%
on 01/07/26
+2.55 (+2.48%)
since 12/19/25
3-Month
84.02 +25.26%
on 10/28/25
112.29 -6.28%
on 01/07/26
+17.94 (+20.55%)
since 10/21/25
52-Week
53.56 +96.49%
on 04/09/25
112.29 -6.28%
on 01/07/26
+31.77 (+43.24%)
since 01/21/25

Most Recent Stories

More News
2 Value Stocks Worth Investigating and 1 That Underwhelm

2 Value Stocks Worth Investigating and 1 That Underwhelm

LGIH : 53.52 (-0.17%)
INCY : 105.11 (+2.43%)
VC : 95.65 (+4.33%)
3 Value Stocks Worth Investigating

3 Value Stocks Worth Investigating

RELY : 13.95 (+2.12%)
NRDS : 12.85 (+0.31%)
INCY : 105.11 (+2.43%)
2 Mid-Cap Stocks with Exciting Potential and 1 We Question

2 Mid-Cap Stocks with Exciting Potential and 1 We Question

CW : 662.49 (+1.85%)
KHC : 22.30 (-6.14%)
INCY : 105.11 (+2.43%)
Why Incyte (INCY) Stock Is Trading Up Today

Why Incyte (INCY) Stock Is Trading Up Today

INCY : 105.11 (+2.43%)
Earnings Preview: What To Expect From Incyte's Report

Incyte is scheduled to release its fourth-quarter results soon, with analysts projecting double-digit surge in its bottom line figure.

XLV : 158.07 (+1.72%)
$SPX : 6,897.72 (+1.48%)
INCY : 105.11 (+2.43%)
2 Cash-Heavy Stocks Worth Investigating and 1 Facing Challenges

2 Cash-Heavy Stocks Worth Investigating and 1 Facing Challenges

INCY : 105.11 (+2.43%)
PCTY : 140.66 (+2.18%)
CLOV : 2.60 (+0.39%)
Incyte (INCY) Stock Is Up, What You Need To Know

Incyte (INCY) Stock Is Up, What You Need To Know

INCY : 105.11 (+2.43%)
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi ® /Minjuvi ® ) and lenalidomide in addition to R-CHOP met its...

INCY : 105.11 (+2.43%)
2 Safe-and-Steady Stocks Worth Your Attention and 1 Facing Challenges

2 Safe-and-Steady Stocks Worth Your Attention and 1 Facing Challenges

MA : 527.07 (-0.88%)
STRA : 85.44 (+2.01%)
INCY : 105.11 (+2.43%)
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi ® (tafasitamab) in combination with rituximab and lenalidomide...

INCY : 105.11 (+2.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 108.16
2nd Resistance Point 106.01
1st Resistance Point 104.31
Last Price 105.11
1st Support Level 100.46
2nd Support Level 98.31
3rd Support Level 96.61

See More

52-Week High 112.29
Last Price 105.11
Fibonacci 61.8% 89.86
Fibonacci 50% 82.93
Fibonacci 38.2% 75.99
52-Week Low 53.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar